

**Supplementary Table 1.** Reagents and thermal profile for integrase amplification.

Reagents	RT-PCR	1 <sup>st</sup> PCR	Nested PCR
	(for RNA)	(for DNA)	(RNA and DNA)
OneStep RT-PCR kit (QIAGEN) enzyme	1 µl	--	--
GoTaq G2 Hot Start colorless mastermix (Promega)	--	12.5 µl	--
BioTaq DNA polymerase (Bioline)	--	--	0.75 U
RNasin (RNase inhibitor) (Promega)	5 U	--	-
MgCl <sub>2</sub>	2.5 mM*	2 mM†	1.8 mM
dNTPs	400 µM	200 µM†	200 µM
Each primer	0.6 µM	0.4 µM	0.4 µM
Reaction volume	25 µl	25 µl	25 µl
<hr/>			
Thermal cycling profile			
<hr/>			
Reverse transcription	30 min 50°C	--	--
Hot start activation	15 min 95°C	--	--
Denaturation	--	2 min 94°C	2 min 94°C
Cycling	40 cycles	35 cycles	40 cycles
Denaturation	30 sec 94°C	30 sec 94°C	30 sec 94°C
Annealing	1 min 55°C	45 sec 55°C	45 sec 56°C
Extension	90 sec 72°C	1 min 72°C	1 min 72°C
Final extension	7 min 72°C	7 min 72°C	5 min 72°C

\* Included in the 2x kit mastermix; † Included in the 5x kit buffer.

**Supplementary Table 2.** Primers used in the integrase amplification and sequencing.

Oligo	Use	Direction	HXB2 position	Sequence
RTDS-N-S	1st PCR/RT-PCR	sense	3132-3157	5'- ATA GGG CAG CAT AGA RCA AAA ATA GA
5'HIV-O-A	1st PCR/RT-PCR	antisense	5239-5266	5'- CTC CTG TAT GCA GAC CCC AAT ATG TTG T
INTS	nested PCR/ sequencing	sense	4160-4182	5'- AGC ACA CAA AGG AAT TGG AGG AA
5'HIVNA	nested PCR/ sequencing	antisense	5192-5220	5'- CCC TAG TGG GAT GTG TAC TTC TGA ACT TA
IN-MED-S	sequencing	sense	4647-4671	5'- GGC ATT CCC TAC AAT CCC CAA AGT C
B2-A-N	sequencing	antisense	5043-5067	5'- AAT CAT CAC CTG CCA TCT GTT TTC C

**Supplementary Table 3.** Codon usage and resistance cost of INSTI resistance mutations in subtype B and non-B subtype strains.

Position	Codon	Subtype B (N=2016)		Non-subtype B (N=680)		Resistance mutations		
		N	%	N	%	AA*	Codon†	SC‡
E92	GAA	591	29	624	92	Q	CAA	5.8
	GAG	1281	64	39	5.7	Q	CAG	5.8
	GAN	137	6.8	7	1.0			
	Others	7	0.3	10	1.5			
T97	ACA	1928	96	647	95	A	GCA	1
	ACT	7	0.35	3	0.44	A	GCT	1
	ACC	8	0.40			A	GCC	1
	ACG	10	0.50			A	GCG	1
	ACN	14	0.69	7	1.0			
	Others	49	2.4	23	3.4			
G118	GGA	24	1.2	11	1.6	R	AGA	1
	GGT	136	6.7	86	13	R	CGT	5.8
	GGC	1784	88	563	83	R	AGG	4.4
	GGG	7	0.35	1	0.15	R	AGG	1
	GGN	62	3.1	19	2.8			
	Others	3	0.15					
E138	GAA	1935	96	646	95	K	AAA	1
	GAG	38	1.9	17	2.5	K	AAG	1
	GAN	16	0.79	9	1.3			
	otros	27	1.3	8	1.2			
G140	GGA	72	3.6	501	74	S	AGC	7.4
	GGT	321	16	11	1.6	S	AGT	1
	GGC	1454	72	53	7.8	S	AGC	1
	GGG	30	1.5	94	14	S	AGC	3.9
	GGN	97	4.8	18	2.6			
	Others	42	2.1	3	0.44			
Q148	CAA	1870	93	601	88	H/R	CAC/CGA	1.8/1
	CAG	81	4.0	71	10	H/R	CAC/CGG	5.8/1
	CAN	47	2.3	4	0.59			
	Others	18	0.9	4	0.59			
N155	AAT	1848	92	647	95	H	CAT	1.8
	AAC	79	3.9	11	1.6	H	CAC	1.8
	AAN	38	1.9	7	1.0			
	Others	51	2.5	15	2.2			
G163	GGA	1611	80	321	47	R	AGA	1
	GGT	10	0	2	0.29	R	CGT	5.8
	GGC	9	0	2	0.29	R	CGC	5.8
	GGG	163	8.1	282	41	R	AGG	1
	GGN	69	3.4	20	2.9			
	Others	154	7.6	53	7.8			
D232	GAT	1577	78	150	22	N	AAT	1
	GAC	213	11	495	73	N	AAC	1
	Others	226	11	36	5.3			
R263	AGA	1810	90	586	86	K	AAA	1
	AGG	142	7.0	72	11	K	AAG	1
	AGN	54	2.7	16	2.4			
	Others	10	0.50	6	0.88			

\*AA: Amino acid change which INSTI resistance. † Triplet with the lowest substitution cost according to Theys et al. 2019. ‡SC: Substitution cost (score defined for each triplet according to Theys et al. 2019).

**Supplementary Figure 1.** Frequency of INSTI-resistance mutations in subtype B and non-B subtype infections. Only mutations with statistically significant differences are shown.

